Galvin James E, Roe Catherine M, Xiong Chengjie, Morris John C
Departments of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park, Suite 130, St. Louis, MO 63108, USA.
Neurology. 2006 Dec 12;67(11):1942-8. doi: 10.1212/01.wnl.0000247042.15547.eb.
To establish the validity, reliability, and discriminative properties of the AD8, a brief informant interview to detect dementia, in a clinic sample.
We evaluated 255 patient-informant dyads. We compared the number of endorsed AD8 items with an independently derived Clinical Dementia Rating (CDR) and with performance on neuropsychological tests. Construct and concurrent validity, test-retest, interrater and intermodal reliability, and internal consistency of the AD8 were determined. Receiver operator characteristic curves were used to assess the discriminative properties of the AD8.
Concurrent validity was strong with AD8 scores correlating with the CDR (r = 0.75, 95% CI 0.63 to 0.88). Construct validity testing showed strong correlation between AD8 scores, CDR domains, and performance on neuropsychological tests. The Cronbach alpha of the AD8 was 0.84 (95% CI 0.80 to 0.87), suggesting excellent internal consistency. The AD8 demonstrated good intrarater reliability and stability (weighted kappa = 0.67, 95% CI 0.59 to 0.75). Both in-person and phone administration showed equal reliability (weighted kappa = 0.65, 95% CI 0.57 to 0.73). Interrater reliability was very good (Intraclass correlation coefficient = 0.80, 95% CI 0.55 to 0.92). The area under the curve was 0.92 (95% CI 0.88 to 0.95), suggesting excellent discrimination between nondemented individuals and those with cognitive impairment regardless of etiology.
The AD8 is a brief, sensitive measure that validly and reliably differentiates between nondemented and demented individuals. It can be used as a general screening device to detect cognitive change regardless of etiology and with different types of informants.
在临床样本中确立用于检测痴呆的简易知情者访谈工具AD8的有效性、可靠性和区分特性。
我们评估了255对患者-知情者组合。我们将认可的AD8项目数量与独立得出的临床痴呆评定量表（CDR）以及神经心理测试表现进行比较。确定了AD8的结构效度和同时效度、重测信度、评分者间信度和多形式信度以及内部一致性。使用受试者工作特征曲线评估AD8的区分特性。
同时效度很强，AD8得分与CDR相关（r = 0.75，95%可信区间0.63至0.88）。结构效度测试显示AD8得分、CDR领域以及神经心理测试表现之间有很强的相关性。AD8的Cronbach α系数为0.84（95%可信区间0.80至0.87），表明内部一致性极佳。AD8显示出良好的评分者内信度和稳定性（加权kappa = 0.67，95%可信区间0.59至0.75）。面对面和电话施测显示出同等的信度（加权kappa = 0.65，95%可信区间0.57至0.73）。评分者间信度非常好（组内相关系数 = 0.80，95%可信区间0.55至0.92）。曲线下面积为0.92（95%可信区间0.88至0.95），表明无论病因如何，在非痴呆个体和有认知障碍的个体之间有极佳的区分度。
AD8是一种简短、敏感的测量工具，能有效且可靠地区分非痴呆和痴呆个体。它可作为一种通用的筛查工具，用于检测无论病因如何且有不同类型知情者的认知变化。
